The role of the reporting framework MIATA within current efforts to advance immune monitoring

Journal of Immunological Methods

Volumn 409, Issue , 2014, Pages 6-8

  Janetzki, Sylvia ^a,f   Britten, Cedrik M ^b   Davis, Mark M ^c   Hoos, Axel ^d   Huber, Christoph ^e   Kalos, Michael ^g   Levitsky, Hyam I ^h   Maecker, Holden T ^c   Melief, Cornelius J M ⁱ   O'Donnell Tormey, Jill ^j   Odunsi, Kunle ^k   Old, Lloyd ^l   Ottensmeier, Christian ^m   Roep, Bart O ⁱ   Romero, Pedro ⁿ   van der Burg, Sjoerd ⁱ   Walter, Steffen ^h  

^a ZellNet Consulting Inc   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c STANFORD UNIVERSITY   (United States)

^d GLAXOSMITHKLINE   (United States)

^e Association for Immunotherapy of Cancer   (United States)

^f ZellNet Consulting   (United States)

^g ELI LILLY AND COMPANY   (United States)

^h Roche ^*  (Germany)

ⁱ LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^j Cancer Research Institute   (United States)

^k Roswell Cancer Park Institute   (United States)

^l LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^m UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

ⁿ UNIVERSITY OF LAUSANNE   (Switzerland)

more..

Author keywords

Immune assays; Immune monitoring; MIATA; Reporting

Indexed keywords

BIOLOGICAL MARKER;

AUTOIMMUNITY; BIOLOGICAL MONITORING; CELL ASSAY; CELL FUNCTION; CLINICAL DECISION MAKING; CLINICAL IMMUNOLOGY; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HUMAN; IMMUNE CELL FUNCTION ASSAY; IMMUNOASSAY; IMMUNOCOMPETENT CELL; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INFECTION; LETTER; MINIMAL INFORMATION ABOUT T CELL ASSAY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; QUALITY CONTROL; SERODIAGNOSIS;

IMMUNE ASSAYS; IMMUNE MONITORING; MIATA; REPORTING;

CONSENSUS; COOPERATIVE BEHAVIOR; GUIDELINE ADHERENCE; HUMANS; IMMUNOLOGIC TESTS; IMMUNOTHERAPY; INTERNATIONAL COOPERATION; LABORATORIES; LABORATORY PROFICIENCY TESTING; MONITORING, IMMUNOLOGIC; OBSERVER VARIATION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84906086475     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2014.05.003     Document Type: Letter

References (10)

1. Attig S., Price L., Janetzki S., Kalos M., Pride M., McNeil L., Clay T., Yuan J., Odunsi K., Hoos A., Romero P., Britten C.M. A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. J. Transl. Med. 2011, 9:108.
2. Britten C.M., Janetzki S., van der Burg S.H., Huber C., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., O'Donnell-Tormey J., Odunsi K., Old L.J., Pawelec G., Roep B.O., Romero P., Hoos A., Davis M.M. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol. Immunother. 2011, 60:15-22.
3. Britten C.M., Janetzki S., Butterfield L.H., Ferrari G., Gouttefangeas C., Huber C., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J., O'Donnell-Tormey J., Odunsi K., Old L.J., Ottenhoff T.H., Ottensmeier C., Pawelec G., Roederer M., Roep B.O., Romero P., van der Burg S.H., Walter S., Hoos A., Davis M.M. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 2012, 37:1-2.
4. Britten C.M., Walter S., Janetzki S. Immunological monitoring to rationally guide AAV gene therapy. Front. Immunol. 2013, 4:273.
5. Cron A., Gouttefangeas C., Frelinger J., Lin L., Singh S.K., Britten C.M., Welters M.J., van der Burg S.H., West M., Chan C. Hierarchical modeling for rare event detection and cell subset alignment across flow cytometry samples. PLoS Comput. Biol. 2013, 9:e1003130.
6. Janetzki S., Britten C.M. The impact of harmonization on ELISPOT assay performance. Methods Mol. Biol. 2012, 792:25-36.
7. Janetzki S., Britten C.M., Kalos M., Levitsky H.I., Maecker H.T., Melief C.J.M., Old L.J., Romero P., Hoos A., Davis M.M. "MIATA"-minimal information about T cell assays. Immunity 2009, 31:527-528.
8. McNeil L.K., Price L., Britten C.M., Jaimes M., Maecker H., Odunsi K., Matsuzaki J., Staats J.S., Thorpe J., Yuan J., Janetzki S. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A 2013, 83:728-738.
9. Singh S.K., Tummers B., Schumacher T.N., Gomez R., Franken K.L., Verdegaal E.M., Laske K., Gouttefangeas C., Ottensmeier C., Welters M.J., Britten C.M., van der Burg S.H. The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunol. Immunother. 2013, 62:489-501.
10. van der Burg S.H., Kalos M., Gouttefangeas C., Janetzki S., Ottensmeier C., Welters M.J., Romero P., Britten C.M., Hoos A. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 2011, 3. (108 ps44).